Latest Breaking News On - Patients with advanced - Page 3 : comparemela.com

Optimal Sequencing in Patients With Advanced HCC

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Hepatocellular carcinomaRecent updatesEvolving treatment paradigmsPatients with advancedRecent data updates hepatocellular carcinomaHcc treatmentsHepatocellular carcinoma treatmentsEarly stage hepatocellular carcinomaHcc risk factorsPatients with hccHcc prognosisHepatocellular carcinoma prognosisHepatocellular carcinoma diagnosisClinical work upMolecular testing hccHcc diagnosis challenges

Merck Announces Second-Quarter 2023 Financial Results

Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth.

United statesRobertm davisAdempas verquvoWorld health organization groupAmerican society of clinical oncologySichuan kelun pharmaceutical co ltdExchange commissionAnimal healthMerck coNet loss attributable to merck co incPrometheus biosciences incImago biosciences incMerck co incAlliance revenueDrug administrationStatement of merck co inc

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomNew yorkLigia vela reidBrandon owensLeonarda farberPierre louis germainUniversity of texas md anderson cancer centerCommunications departmentInvestor relations departmentExchange commissionFrench financial markets authority autoritDrug administrationGiven the companyFirst patient injected

Lazertinib Versus Gefitinib as First-line Treatment in EGFR-mutated Advanced NSCLC

1. Progression-free survival was longer in the lazertinib group vs the gefitinib group (20.6 months vs 9.7 months, with HR 0.45), however, OS data were immature. 2. Treatment-related adverse events were similar across both groups, however, lazertinib had higher rates of parasthesia and pruritus but lower levels of ALT elevations and diarrhea. Evidence Rating Level:

Rating levelPatients with advancedAfter previousMedian dor

New Long-Term Data from the CHRYSALIS Study Show Median

Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive.

United statesRegion flamandeNoord hollandSouth koreaJanssen cilag gmbMartin vogelHoon leeKiran patelNational cancer instituteJanssen pharmaceutical companiesAmerican society of clinical oncologySamsung medical centerEuropean commissionExchange commissionYuhan corporationCompanies of johnson